secwatch.observer — SEC 8-K summary
======================================

Issuer:     TScan Therapeutics, Inc. (TCRX)
CIK:        0001783328
Form:       8-K
Filed at:   2023-05-10T23:59:59+00:00
Accession:  0000950170-23-020082
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TScan reports Q1 net loss $22.6M; Amgen partnership adds $30M upfront, extends cash runway
--------------------------------------------------------------------------------

- Net loss $22.6M vs $16.2M in Q1 2022; revenue $6.8M, up from $3.0M on Novartis collaboration wind-down.
- Amgen partnership for Crohn's disease targets: $30M upfront, potential milestones >$500M; cash runway extended into Q3 2024.
- Phase 1 heme study: patients enrolled in all three arms; TSC-101 cleared for second dose level (two doses 40 days apart).
- Cash and equivalents $95.6M at Mar 31, 2023; combined with Amgen upfront supports operations into Q3 2024.
- Appointed Dr. Barbara Klencke to Board of Directors; she previously led oncology development at Sierra/GSK.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783328/000095017023020082/0000950170-23-020082-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783328/000095017023020082/tcrx-20230510.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-020082

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer